Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

Oral edaravone was approved in 2022 based on bioequivalence and long-term safety studies comparing it with the IV edaravone ...

SAVANNAH, Georgia — Heart problems are common in the vast majority of neuromuscular disorders, and cardiac monitoring of ...

SAVANNAH, Ga. -- One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients ...

Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary ...

The University of Alabama at Birmingham (UAB) provides an ACGME accredited, one year, neuromuscular medicine fellowship program. Our fellowship offers comprehensive training in clinical neuromuscular ...

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular researchPresentations ...

Alexion to present data from its leading generalised myasthenia gravis portfolio at 2024 AANEM annual meeting: Cambridge, UK Friday, October 11, 2024, 13:30 Hrs [IST] Alexion, Ast ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Brussels, Belgium Monday, October 14, 2024, 17:00 Hrs [IST] ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia ...